Response to Chemotherapy Necessary in G2 and G3 Neuroendocrine Carcinomas

Walter I Kocha BSc MD FRCPC, London Regional Cancer Center, Western University, London Ontario Canada

Introduction/Background

Although approaches to treatment of G1 and G3 neuroendocrine carcinomas are generally agreed upon, treatment of G2 disease and residual disease from treated G3 is problematic. As the most threatening component is the higher proliferating component, therapy should be initially directed to that constituent of the disease.

Heterogeneity of Tumor Cell Populations: The tumor cell population can be conceived of in several different ways. In the simplest form the tumor cell population could be homogeneous and have variable rates of proliferation yielding a discrete proliferation fraction that may measured in individual tumors over a wide range. Currently the Ki-67 index and number of mitoses per 10 high power fields are considered to represent this proliferation fraction. Alternatively the tumor mass may of at least two populations of cells with different proliferation rates. The evidence indicates that many cytotoxic therapies result in little effect in low proliferative cells. On the other hand there is ample evidence that cytotoxic therapies have its major effect on proliferating cells. Current practice accepts that neuroendocrine carcinomas with high Ki67 (>20%) are often sensitive to chemotherapy and should be offered that chemotherapy, the expected change in tumor diameter was calculated as defined and utilized by the RECIST criteria. The treatment of G2 neuroendocrine neoplasms was reviewed at an international meeting in 2012, analysis of existing data led to the conclusion that this grade of disease exhibited widely different behavior depending on proliferative considerations. Base on the RECIST 1.1 criterion of a decrease in diameter of greater than 30% required classification as response, the standard geometric calculation predicts that the threshold for partial response could not be satisfied unless the initial proliferative fraction is 66% or greater.

Materials and Methods

The mathematical determination of tumor volume related to tumor diameter was considered assuming that the perfectly spherical tumor was the least sensitive case. As volume can be calculated with \( V = \frac{4}{3} \pi r^3 \), the diameter then can be calculated with respect volume by \( D = \sqrt[3]{\frac{3V}{4\pi}} \). Varying the total fraction of tumor volume that was of high proliferation and assuming that all of that tumor compartment was eradicated by chemotherapy, the expected change in tumor diameter was calculated. The change in volume required for 10%, 20% and 30% decrease in diameter. The latter is the defined value required for declaration of partial response by the RECIST 1.1 criteria.

Results

The capability of tumor measurement to resolve significant changes in tumor diameter considering potential sources of error including registration error, fuzzy tumor edges, inter-observer and intra-observer error is at minimum 10%. Experiments in such error measurement error yielded errors of 20%. In RECIST 1.0 a minimum of 20% change was required to declare progression in order to minimize these sources of measurement error. This represents a 50% change in tumor volume. Based on the RECIST 1.1 criterion of a decrease in diameter of greater than 30% required classification as response, the standard geometric calculation predicts that the threshold for partial response could not be satisfied unless the initial proliferative fraction is 66% or greater.

Implications

The concept of sequential treatment of high proliferative followed by low proliferative disease appears attractive and should be tested. Our best current data indicates that the differential sensitivity of these subpopulations have little overlap and thus require separate considerations. Considering a proliferative-therapeutic based paradigm, a further subdivision of G status might include a partition such as:

- G2A: 3-10%
- G2B: 11-19%
- G3A: 20-65%
- G3B: 66-100%

In such a scheme the G2B and G3A subgroups would represent the grades of disease for which staged therapies may prove to be of advantage over “monotherapy”. These issues and strategies deserve further consideration, discussion and ultimately testing.

Conclusions

Patients with G2 and low G3 disease should have at least stable disease to consider transitioning to treat residual disease as G1 disease. It is hoped that approaches such as these may serve as the basis for trials and further data greatly needed in these situations.

Implications in Therapy Development

Patients with G2 and low G3 disease should have at least stable disease to consider transitioning to treat residual disease as G1 disease. It is hoped that approaches such as these may serve as the basis for trials and further data greatly needed in these situations.

<table>
<thead>
<tr>
<th>Group</th>
<th>Increase in Diameter</th>
<th>Decrease in Diameter</th>
<th>Decrease in Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>G2A</td>
<td>3-10%</td>
<td>0</td>
<td>26</td>
</tr>
<tr>
<td>G2B</td>
<td>11-19%</td>
<td>10</td>
<td>50</td>
</tr>
<tr>
<td>G3A</td>
<td>20-65%</td>
<td>20</td>
<td>66</td>
</tr>
<tr>
<td>G3B</td>
<td>66-100%</td>
<td>30</td>
<td>66</td>
</tr>
</tbody>
</table>

Abstract

Response to Chemotherapy Necessary in G2 and G3 Neuroendocrine Carcinomas

Walter I Kocha BSc MD FRCPC, London Regional Cancer Center, Western University, London Ontario Canada

Introduction/Background

Although approaches to treatment of G1 and G3 neuroendocrine carcinomas are generally agreed upon, treatment of G2 and G3 disease is problematic. Therapy should initially be directed to the highest proliferating component with chemotherapy. Residual disease could then sequentially be treated with the modalities relevant to that G1 tumor such as PRRT. What degree of response therefore would be required utilizing chemotherapy for the rapidly proliferating component?

Aims

To determine the expected response of tumor to therapy using RECIST criteria when the proliferative tumor fraction was successfully treated.

Materials and methods

A simple mathematical model of tumor volume related to tumor diameter was considered assuming that the perfectly spherical tumor was the least sensitive case. Varying the total fraction of tumor volume that was of high proliferation and assuming that all of that tumor compartment was eradicated by chemotherapy, the expected change in tumor diameter was calculated as defined and used by the RECIST criteria.

Results

Based on the RECIST criterion of a decrease in diameter of greater than 30% required classification as response, the model predicts that the threshold for partial response could not be satisfied unless the initial proliferative fraction is 66% or greater.

Conclusions

Patients with G2 and low G3 disease should have at least stable disease to consider transitioning to treat residual disease as G1 disease. It is hoped that approaches such as these may serve as the basis for trials and further data greatly needed in these situations.